Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases Seismic Therapeutic, Inc., a machine learning-driven immunology company, has announced a significant milestone in its journey toward developing transformative therapies for autoimmune diseases. The company has dosed the first…
Care Access Acquires Brazil-Based Clinical Research Center CEMEC Care Access, a globally recognized healthcare and clinical research organization, has announced the successful acquisition of Centro Multidisciplinar de Estudos Clínicos (CEMEC), a leading clinical research center based in Brazil. This acquisition…
NeoGenomics Acquires Pathline to Strengthen Oncology Testing in the Northeast NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, has announced its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. This acquisition…
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease Agomab Therapeutics NV (“Agomab”), a biotechnology company focused on developing innovative treatments for fibrotic diseases, has announced positive interim results from its ongoing STENOVA Phase 2a…
Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative, non-addictive treatments for pain management, central nervous system (CNS) disorders, post-traumatic stress disorder, and…
Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) recently showcased promising preclinical data supporting the advancement of two first-in-class, RNA interference (RNAi)-based investigational therapeutics, ARO-INHBE and ARO-ALK7, for the treatment of obesity and…
Tris Pharma Reports Positive Phase 3 Results for Cebranopadol in Acute Pain Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company dedicated to developing innovative pain management therapies, has announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal clinical trial…
NeuPath Health Launches Arthrosamid® for Knee Osteoarthritis NeuPath Health Inc. (TSXV: NPTH) (“NeuPath” or the “Company”), a leading provider of chronic pain treatment through its extensive network of clinics, has achieved a groundbreaking milestone in North America. The company proudly…
Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products Parse Biosciences, a leading innovator in scalable and accessible single-cell sequencing technology, has reaffirmed its commitment to advancing its Evercode™ single-cell chromatin accessibility products. This announcement marks a significant milestone for…
Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies Gensaic, Inc., a pioneering biotechnology company leveraging AI-driven protein design and biological insights to develop precision ligands for targeted drug delivery, has announced a major discovery and license collaboration with…
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled promising preclinical data on SOT109, a next-generation antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). These findings reinforce the strong therapeutic potential of SOT109 in treating colorectal cancer (CRC) and…
Revvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test Revvity, Inc. (NYSE: RVTY) has announced the launch of EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG), which has received the CE mark. This novel assay is designed to support both the…